# Safety, PK and Effectiveness of IV Peramivir Versus Oseltamivir in Pediatric Subjects With Uncomplicated Influenza

> **NCT02369159** · PHASE3 · COMPLETED · sponsor: **BioCryst Pharmaceuticals** · enrollment: 137 (actual)

## Conditions studied

- Influenza

## Interventions

- **DRUG:** Peramivir
- **DRUG:** Oseltamivir

## Key facts

- **NCT ID:** NCT02369159
- **Lead sponsor:** BioCryst Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-03-11
- **Primary completion:** 2019-10-28
- **Final completion:** 2020-05-14
- **Target enrollment:** 137 (ACTUAL)
- **Last updated:** 2021-03-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02369159

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02369159, "Safety, PK and Effectiveness of IV Peramivir Versus Oseltamivir in Pediatric Subjects With Uncomplicated Influenza". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02369159. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*